Maria Kefalis
Viewpoint: GlaxoSmithKline abandonment of rare disease gene-therapy drug program because it’s not a money generator hurts children
When GlaxoSmithKline, long a global leader in the effort to pioneer gene replacement therapies, announced it would halt its drug ...
